Brief: Aravive Announces Positive Preliminary Data From Phase 1B Trial Evaluating Batiraxcept In Combination With Cabozantinib

Aravive

12/11/2021 12:40

Nov 12 (Reuters) - Aravive Inc  ARAV.O :
    * ARAVIVE ANNOUNCES POSITIVE PRELIMINARY DATA FROM PHASE 1B
TRIAL
EVALUATING BATIRAXCEPT (AVB-500) IN COMBINATION WITH
CABOZANTINIB FOR TREATMENT OF CLEAR CELL RENAL CELL CARCINOMA
    * ARAVIVE INC - LOOK FORWARD TO INITIATING PHASE 2 TRIAL IN
Q4 OF
2021

Source text for Eikon:  ID:nGNX4DMB4V 
Further company coverage:  ARAV.O 

 ((Reuters.Briefs@thomsonreuters.com;))